Drug intelligence / Profile preview

Xinbojin

Development stage: Unknown
Lead developer: Beijing SL Pharmaceutical
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Xinbojin (欣博金) is a brand name used by Beijing SL Pharmaceutical for two distinct oncology drugs approved in China: nimustine hydrochloride and ibrutinib. Nimustine hydrochloride is an alkylating agent of the nitrosourea class, administered intravenously as a lyophilized powder for injection, primarily used to treat brain tumors, lung cancer, gastric cancer, and other solid tumors. Ibrutinib is a small-molecule, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK), administered orally as capsules, approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Waldenström's macroglobulinemia (WM).

Brand names: Xinbojin欣博金
Other names: IbrutinibNimustine hydrochloride伊布替尼盐酸尼莫司汀

Targets

BTK (Bruton tyrosine kinase)DNA

Beyond the preview

Go deeper on Xinbojin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinbojin.